News & Updates

Use of ranibizumab and lower-dose bevacizumab results in a higher rate of retreatment as compared with higher-dose bevacizumab use in patients with retinopathy of prematurity (ROP) initially treated with antivascular endothelial growth factors (anti-VEGFs), a study has shown.

A small but promising study showed that acalabrutinib, an oral BTK* inhibitor approved for B-cell malignancies**, may reduce or even prevent clinical reactivity to peanuts in peanut-allergic adults.

Bivalent boosters provide substantial additional protection against severe COVID-19 caused by the Omicron variant. On August 31, 2022, the US Food and Drug Administration (FDA) approved bivalent COVID-19 vaccines for use as a single booster dose.

Data from a French study presented at CROI 2023 support the use of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/FTC/TAF) in the management of paediatric patients with HIV.

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.